Stock listing
TPEx:4192 SynCore Biotechnology Co., Ltd. (杏國) 股價
Follow SynCore Biotechnology Co., Ltd. into a list and get an email when it puts out news.
Share price · TPEX:4192
$15.75 TWD -0.45 (-2.8%)
Close on Nov 20, 2026
- Day range
- $15.05 – $15.75 TWDNov 20, 2026
- Volume
- 9,010 sharesNov 20, 2026
- Market cap
- $553.8M TWDAt the close on Nov 20, 2026 · price × 35.16M shares outstanding
- 52-week range
- $15.05 – $26.50 TWDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $217,909 TWDMedian day 7,000 shares · 8 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TPEX:4192 · TWD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $15.75 | -0.45 | -2.8% | $15.10 | $15.75 | $15.05 | 9,010 | |
| $16.20 | +0.45 | +2.9% | $16.45 | $16.45 | $16.20 | 4,871 | |
| $15.75 | +0.55 | +3.6% | $15.20 | $15.75 | $15.20 | 3,271 | |
| $15.20 | -0.40 | -2.6% | $15.20 | $15.20 | $15.10 | 8,001 | |
| $15.60 | -0.15 | -1.0% | $15.60 | $15.70 | $15.60 | 13,269 | |
| $15.75 | -0.20 | -1.3% | $15.75 | $15.75 | $15.75 | 4,920 | |
| $15.95 | -0.50 | -3.0% | $15.70 | $15.95 | $15.55 | 12,219 | |
| $16.45 | -0.10 | -0.6% | $15.60 | $16.45 | $15.60 | 21,008 | |
| $16.55 | +0.75 | +4.7% | $16.20 | $16.55 | $16.20 | 3,001 | |
| $15.80 | -0.80 | -4.8% | $15.30 | $16.15 | $15.30 | 12,001 | |
| $16.60 | +0.05 | +0.3% | $16.70 | $16.70 | $16.10 | 5,001 | |
| $16.55 | -0.20 | -1.2% | $16.75 | $16.75 | $16.05 | 7,000 | |
| $16.75 | -0.10 | -0.6% | $16.45 | $16.75 | $16.05 | 15,000 | |
| $16.85 | -0.05 | -0.3% | $16.50 | $16.85 | $16.50 | 8,432 | |
| $16.90 | +0.40 | +2.4% | $16.50 | $16.90 | $16.30 | 19,611 | |
| $16.50 | -0.30 | -1.8% | $16.75 | $16.75 | $16.50 | 21,145 | |
| $16.80 | -0.40 | -2.3% | $17.00 | $17.00 | $16.80 | 4,535 | |
| $17.20 | +0.20 | +1.2% | $17.00 | $17.20 | $17.00 | 8,001 | |
| $17.00 | 0.00 | 0.0% | $17.00 | $17.00 | $17.00 | 0 | |
| $17.00 | -0.45 | -2.6% | $17.10 | $17.10 | $17.00 | 3,001 | |
| $17.45 | +0.30 | +1.7% | $17.35 | $17.45 | $17.35 | 2,001 | |
| $17.15 | -1.20 | -6.5% | $17.25 | $17.65 | $17.15 | 33,673 | |
| $18.35 | +0.15 | +0.8% | $18.00 | $18.35 | $18.00 | 6,001 | |
| $18.20 | -0.50 | -2.7% | $17.60 | $18.20 | $17.60 | 5,651 | |
| $18.70 | 0.00 | 0.0% | $18.70 | $18.70 | $18.70 | 0 | |
| $18.70 | +0.80 | +4.5% | $17.85 | $18.70 | $17.60 | 6,500 | |
| $17.90 | -0.10 | -0.6% | $18.00 | $18.00 | $17.90 | 17,000 | |
| $18.00 | +0.20 | +1.1% | $17.80 | $18.10 | $17.75 | 33,002 | |
| $17.80 | +0.30 | +1.7% | $17.55 | $17.80 | $17.50 | 42,000 | |
| $17.50 | -0.30 | -1.7% | $17.80 | $17.80 | $17.50 | 52,018 | |
| $17.80 | -0.85 | -4.6% | $18.10 | $18.25 | $17.75 | 55,000 | |
| $18.65 | 0.00 | 0.0% | $18.65 | $18.65 | $18.65 | 0 | |
| $18.65 | 0.00 | 0.0% | $18.65 | $18.65 | $18.65 | 0 | |
| $18.65 | +0.20 | +1.1% | $18.45 | $18.65 | $18.45 | 4,500 | |
| $18.45 | +0.30 | +1.7% | $18.45 | $18.45 | $17.65 | 5,122 | |
| $18.15 | 0.00 | 0.0% | $18.15 | $18.15 | $18.15 | 0 | |
| $18.15 | +0.05 | +0.3% | $18.15 | $18.15 | $18.15 | 1,000 | |
| $18.10 | -0.50 | -2.7% | $18.00 | $18.10 | $17.90 | 11,801 | |
| $18.60 | +0.30 | +1.6% | $18.50 | $18.60 | $18.50 | 6,000 | |
| $18.30 | +0.15 | +0.8% | $17.95 | $18.30 | $17.95 | 7,000 | |
| $18.15 | -1.30 | -6.7% | $18.80 | $18.80 | $17.75 | 28,373 | |
| $19.45 | +0.60 | +3.2% | $18.20 | $19.45 | $18.20 | 5,534 | |
| $18.85 | 0.00 | 0.0% | $18.85 | $18.85 | $18.85 | 0 | |
| $18.85 | +0.60 | +3.3% | $18.20 | $18.85 | $18.20 | 11,000 | |
| $18.25 | -0.65 | -3.4% | $18.25 | $18.25 | $18.25 | 5,000 | |
| $18.90 | +0.35 | +1.9% | $18.55 | $18.90 | $18.40 | 27,172 | |
| $18.55 | -0.30 | -1.6% | $18.40 | $18.70 | $18.40 | 5,000 | |
| $18.85 | 0.00 | 0.0% | $18.85 | $18.85 | $18.85 | 0 | |
| $18.85 | -0.05 | -0.3% | $18.65 | $18.85 | $18.40 | 12,205 | |
| $18.90 | +0.40 | +2.2% | $18.30 | $18.90 | $18.30 | 7,000 | |
| $18.50 | -0.75 | -3.9% | $18.65 | $18.80 | $18.50 | 48,000 | |
| $19.25 | +0.25 | +1.3% | $19.25 | $19.25 | $19.25 | 1,801 | |
| $19.00 | -0.05 | -0.3% | $18.55 | $19.00 | $18.55 | 4,000 | |
| $19.05 | 0.00 | 0.0% | $19.05 | $19.05 | $19.05 | 3,000 | |
| $19.05 | -0.90 | -4.5% | $19.15 | $19.15 | $19.00 | 16,000 | |
| $19.95 | 0.00 | 0.0% | $19.95 | $19.95 | $19.95 | 0 | |
| $19.95 | -0.05 | -0.3% | $19.30 | $19.95 | $19.30 | 29,064 | |
| $20.00 | 0.00 | 0.0% | $19.50 | $20.00 | $19.00 | 30,576 | |
| $20.00 | 0.00 | 0.0% | $20.00 | $20.00 | $19.50 | 12,006 | |
| $20.00 | +0.55 | +2.8% | $19.10 | $20.00 | $19.00 | 13,329 | |
| $19.45 | -0.05 | -0.3% | $19.00 | $20.00 | $19.00 | 11,122 |
Splits
1 split · TPEX:4192 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-3.743 | Consolidation |
- Ticker
- TPEx:4192
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TPEx
- Currency
- TWD
SynCore Biotechnology Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
Valuation
EV/sales 15.6× against a median of 1.7×: the highest of 3 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $408.0M TWD
- P/E
- Loss
- EV/sales
- 15.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.5×
- Gross margin
- 81.4%
- Operating margin
- −185.8%
- Net margin
- −178.5%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| SynCore Biotechnology Co., Ltd. · TPEX:4192 | US$16.80M | US$12.38M | n/a | 15.6× | n/a | 2.5× | −178.5% | 0.0× | n/a |
| Resverlogix Corp. · TSX:RVX | US$18.01M | US$95.55M | n/a | n/a | n/a | n/a | n/a | n/a | 0.26 |
| Initiator Pharma A/S · OMXSTO:INIT | US$16.74M | US$15.65M | n/a | n/a | n/a | 13.4× | n/a | 1.1× | n/a |
| Neurotech International Ltd. · ASX:NTI | US$16.63M | US$15.06M | n/a | n/a | n/a | 41.1× | n/a | 0.0× | n/a |
| Akari Therapeutics PLC · NASDAQ:AKTX | US$16.41M | US$10.66M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.49 |
| Lipocine Inc. · NASDAQ:LPCN | US$16.39M | −US$5.07M | n/a | −1.4× | n/a | 0.8× | −249.2% | 0.0× | 1.18 |
| MaaT Pharma · EURONEXT:MAAT | US$16.11M | US$23.36M | n/a | 4.7× | n/a | n/a | −686.6% | n/a | n/a |
| Elicera Therapeutics AB · OMXSTO:ELIC | US$16.09M | US$10.40M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| Pasithea Therapeutics Corp. · NASDAQ:KTTA | US$16.00M | −US$25.22M | n/a | n/a | −0.1× | 0.4× | n/a | 0.0× | 0.97 |
| Atossa Therapeutics, Inc. · NASDAQ:ATOS | US$15.92M | −US$4.66M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.87 |
| Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX | US$15.76M | −US$17.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.68 |
| Median of the others | US$16.25M | US$10.53M | 1.7× | −0.1× | 0.9× | −467.9% | 0.0× | 0.92 |
Team and board
Officers
| Officer | Role |
|---|---|
| Chih Wen Lee | Founder, Chairman / CEO |
| Hui-Hung Wang | Director of Oncology |
| Muh-Hwan Su | General Manager |
Board
| Director | Role |
|---|---|
| Chih Wen Lee | Founder, Chairman / CEO |
| Yita Lee | Deputy Chairman |
Financials
Annual, in TWD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.0M | 23.3M | 20.2M | 15.9M | 6.94M | 13.3M | 13.0M | 7.71M | 8.14M | 6.90M |
| Cost of revenue | 5.96M | 10.4M | 19.7M | 6.77M | 3.97M | 7.15M | 4.70M | 3.64M | 4.07M | 3.65M |
| Gross profit | 21.1M | 12.9M | 521.0K | 9.09M | 2.97M | 6.19M | 8.27M | 4.07M | 4.07M | 3.25M |
| Research and development | 24.5M | 28.3M | 3.94M | 157.2M | 423.0M | 363.2M | 380.1M | 257.6M | 224.3M | 208.5M |
| Selling, general and administrative | 43.8M | 42.3M | 33.3M | 36.2M | 34.9M | 35.1M | 44.8M | 47.5M | 39.7M | 38.4M |
| Operating income | -47.2M | -57.8M | -37.4M | -186.4M | -456.6M | -395.5M | -416.6M | -301.0M | -260.0M | -243.7M |
| Depreciation and amortization | 17.6M | 18.2M | 19.7M | 40.1M | 52.4M | 56.5M | 16.7M | 8.25M | 46.6M | 46.4M |
| EBITDA | -29.6M | -39.6M | -17.7M | -146.3M | -404.1M | -339.1M | -399.9M | -292.8M | -213.4M | -197.3M |
| Interest expense | 173.0K | 302.0K | 784.0K | 2.27M | 2.04M | 3.39M | 2.04M | 982.0K | 0 | 0 |
| Income before tax | -45.8M | -54.3M | -38.2M | -188.7M | -458.6M | -398.9M | -408.6M | -294.1M | -258.0M | -162.2M |
| Net income | -45.8M | -54.3M | -38.2M | -188.7M | -458.6M | -398.9M | -408.6M | -294.1M | -258.0M | -162.2M |
| Earnings per share, basic | -1.30 | -1.54 | -1.19 | -6.14 | -14.87 | -14.12 | -4.20 | -3.53 | -3.69 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 157.3M | 205.5M | 264.7M | 269.1M | 553.0M | 539.2M | 386.4M | 472.6M | 462.7M | 712.0M |
| Short-term investments | 7.07M | 6.96M | 6.66M | 6.66M | 6.66M | 6.66M | 6.66M | 6.66M | 6.66M | 6.66M |
| Receivables | 5.59M | 2.27M | 35.9M | 54.4M | 131.2M | 170.9M | 24.7M | 22.5M | 20.3M | 15.3M |
| Inventory | 9.68M | 10.1M | 3.12M | 17.5M | 17.2M | 17.9M | 107.7M | 37.4M | 11.5M | 5.99M |
| Current assets | 215.3M | 260.5M | 310.5M | 348.2M | 710.7M | 742.0M | 538.9M | 545.2M | 502.0M | 747.9M |
| Property, plant and equipment | 14.8M | 11.1M | 27.8M | 43.2M | 12.6M | 17.8M | 13.6M | |||
| Total assets | 255.7M | 317.8M | 378.4M | 436.6M | 824.4M | 914.0M | 763.9M | 804.8M | 845.9M | 1.11B |
| Accounts payable | 1.06M | 9.32M | 0 | 315.0K | 655.0K | 11.4M | 732.0K | 367.0K | 751.0K | 4.66M |
| Current liabilities | 10.1M | 22.1M | 21.2M | 186.6M | 381.5M | 348.1M | 133.4M | 63.3M | 55.4M | 49.2M |
| Total debt | 2.11M | 71.8M | 125.5M | 228.8M | ||||||
| Total liabilities | 10.1M | 23.1M | 21.2M | 187.6M | 381.5M | 353.4M | 151.8M | 98.1M | 125.3M | 148.5M |
| Shareholders' equity | 245.6M | 294.7M | 357.1M | 249.0M | 442.9M | 560.6M | 612.0M | 706.7M | 720.6M | 966.4M |
| Shares outstanding | 35.2M | 35.2M | 32.1M | 30.7M | 30.8M | 28.3M | 97.4M | 83.4M | 69.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -38.3M | -49.2M | -82.4M | -209.6M | -229.9M | -316.6M | -418.6M | -272.3M | -202.0M | -195.1M |
| Capital spending | -406.0K | -457.0K | -761.0K | -1.04M | -1.64M | -6.02M | -3.55M | -2.99M | -12.2M | -6.69M |
| Free cash flow | -38.7M | -49.7M | -83.1M | -210.6M | -231.5M | -322.7M | -423.5M | -277.4M | -215.9M | -201.8M |
| Cash from investing | -1.03M | -1.64M | -5.64M | -3.43M | -6.65M | -13.9M | 158.5M | |||
| Cash from financing | 78.7M | -73.2M | 245.3M | 475.1M | 335.8M | 288.9M | -33.5M | 310.7M | ||
| Share buybacks | 324.0M | |||||||||
| Change in cash | -48.2M | -59.2M | -4.45M | -283.8M | 13.7M | 152.9M | -86.3M | 9.96M | -249.3M | 274.1M |
Cap table
Built by 6ix from SynCore Biotechnology Co., Ltd.’s releases
- Common shares
- 35,165,000
- Fully diluted
- 35,165,000
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 35,165,000 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 35,165,000 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Chih Wen Lee | Founder, Chairman / CEO · Since at least Nov 5, 2026 |
| Hui-Hung Wang | Director of Oncology · Since at least Nov 5, 2026 |
| Muh-Hwan Su | General Manager · Since at least Nov 5, 2026 |
| Yita Lee | Deputy Chairman · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about SynCore Biotechnology Co., Ltd.